Passage BioPASG +2.18%30 Net Debt Paydown Yield % is 39.92% as of Jul. 03, 2026, which is 2276% above its 10-year median of 1.68. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,163 Biotechnology companies, Passage Bio ranks better than 97.16% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Passage Bio's Net Debt Paydown Yield % was 39.92%.
Passage Bio (NAS:PASG) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Passage Bio Net Debt Paydown Yield % Related Terms
Passage Bio Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Passage Bio's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PASG vs CTXR, HIND, GTBP: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Passage Bio's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Passage Bio's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 39.92% mean?
Passage Bio (PASG) has a Net Debt Paydown Yield % of 39.92% as of Jul. 03, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Passage Bio and its competitors. This is 2276% above median its historical median of 1.68. Over the past decade, Passage Bio's Net Debt Paydown Yield % has ranged from 0.66 to 39.92. According to the industry distribution chart, Passage Bio ranks #33 out of 1163 companies in the Biotechnology industry, placing it in the top 2.8%.
Is Passage Bio's Net Debt Paydown Yield % too high?
Passage Bio's current Net Debt Paydown Yield % of 39.92% is 2276% above median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 39.92. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Passage Bio's value of 39.92% is 132966.7% above this industry median. Based on the distribution chart, Passage Bio ranks #33 out of 1163 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Net Debt Paydown Yield % compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #33 out of 1163 companies for Net Debt Paydown Yield %. This places Passage Bio in the top 3% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Passage Bio's value of 39.92% is 132966.7% above this benchmark. Historically, Passage Bio's own Net Debt Paydown Yield % has ranged from 0.66 to 39.92 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 0.03, Passage Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Passage Bio's current Net Debt Paydown Yield % of 39.92% is 132966.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current Net Debt Paydown Yield % is 39.92%, which is 2276% above median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Net Debt Paydown Yield % of 39.92%. The current Net Debt Paydown Yield % is 39.92%, which is 2276% above median its 10-year median of 1.68 and 132966.7% above the Biotechnology industry median of 0.03. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Passage Bio (PASG), the current Net Debt Paydown Yield % is 39.92% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score
Get the complete analysis for PASG
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 
